Viromed Medical AG has successfully completed a capital increase, placing 450,000 new registered no-par value shares at a price of EUR 4.50 per share, the company announced. The gross proceeds of approximately EUR 2 million will be used to finance the company's working capital, a move that strengthens the company's financial position as it seeks to expand its cold plasma technology business.
The capital increase, carried out by partially utilizing the Authorized Capital 2025 and excluding shareholders' subscription rights, will increase the share capital from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000, subject to registration in the commercial register. The exclusion of subscription rights means the new shares were placed directly with investors, allowing the company to raise funds quickly and efficiently. This approach can be particularly beneficial for a growth-oriented company like Viromed, which aims to advance the use of cold plasma technology in medicine.
Viromed Medical AG, listed on the stock exchange since October 2022, specializes in the development, manufacture, and distribution of medical products. Its operating business focuses on the distribution of innovative cold plasma technology for medical applications through its wholly owned subsidiary, Viromed Medical GmbH. The company has established a broad customer base in the DACH region and beyond, and it is pursuing the goal of further advancing cold plasma technology in medicine and realizing corresponding growth potential.
The additional working capital is crucial for Viromed to execute its growth strategy. Cold plasma technology is gaining traction in medical applications, including wound healing and disinfection, and Viromed is positioning itself to capitalize on this trend. The funds will likely support ongoing operations, product development, and market expansion, enabling the company to meet increasing demand and invest in its infrastructure.
Investors may view the successful completion of the capital increase as a sign of confidence in Viromed's business model and growth prospects. The placement price of EUR 4.50 per share reflects the company's valuation and the willingness of investors to support its strategic initiatives. The capital increase also enhances the company's equity base, which can improve its ability to secure additional financing if needed.
For stakeholders, this announcement underscores Viromed's commitment to expanding its presence in the medical technology sector. As reported by NEWMEDIAWIRE, the company is well-positioned to leverage its expertise in cold plasma technology to drive future growth. Further details about Viromed Medical AG can be found at www.viromed-medical-ag.de.
The capital increase is a significant step for Viromed, providing the necessary resources to pursue its goals and potentially accelerate the adoption of cold plasma technology in medical settings. With the proceeds, the company can strengthen its market position and continue to innovate, which could lead to long-term value creation for shareholders and improved patient outcomes.
